Shanghai Fosun Pharmaceutical (HKG:2196, SHA:600196) subsidiary Fosun Pharma's (Xuzhou) drug registration application for the Levosalbutamol Hydrochloride Nebuliser Solution was accepted by the National Medical Products Administration of China, a Friday Hong Kong bourse filing said.
The drug is a chemical drug used for the treatment or prevention of bronchospasm in adults and children 6 years and older.
The company, as of the end of 2024, has invested 4.54 million yuan in the research and development of the drug.
免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。